XFOR

X4 Pharmaceuticals, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$3.17

Price (1 Year)

$4.64 $2.59

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %41.6 / %30
Non-compliant assets / Total market cap %102.5 / %30
Non-compliant revenue / Total income %47.4 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.

Website

Analysis (Turkish): XFOR Hissesi Caiz mi, Helal mi? X4 Pharmaceuticals, Inc. Katılım Analizi